Device Trial Radar · NCT07728071
Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 2, 2026
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, single-arm, single-site, post-market device study; all procedures use Veloxion™ per IFU.
Conditions
- BPH (Benign Prostatic Hyperplasia)
Interventions
TURP using the Aulea Veloxion™ Disposable Resectoscope SystemProcedure
TURP will be performed by Aulea Veloxion™ Disposable Resectoscope System. The resectoscopes are single-use and ensure consistent quality and no cross-contamination. The automated fluid management system continuously monitors and manages intravesical pressure while actively evacuating tissue to prevent clogging. The active power generation system optimize plasma generation for effective resection and extended equipment life. This system allows transurethral resection of prostate to be performed in a motorized and highly effective manner. This study is designed to prospectively characterize operational efficiency in real-world BPH resections using the cleared device platform.
Aulea Veloxion™ Disposable Resectoscope SystemDevice
Veloxion™ platform disposable resectoscope is FDA-cleared for treatment of BPH. It is an all-in-one, platform that combines fluid control, video pipeline and energy generator. The resectoscopes are single-use and ensure consistent quality and no cross-contamination. The automated fluid management system continuously monitors and manages intravesical pressure while actively evacuating tissue to prevent clogging. The active power generation system optimize plasma generation for effective resection and extended equipment life. This system allows transurethral resection of prostate to be performed in a motorized and highly effective manner. This study is designed to prospectively characterize operational efficiency in real-world BPH resections using the cleared device platform.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in total procedure time versus a pre-specified benchmarkTime frame: Perioperative
- Difference in case cost versus a pre-specified benchmarkTime frame: Perioperative
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prince of Wales Hospital
Shatin, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.